Products

Signal Tracker Data Platform Data Enrichment API Intelligence desk

Solutions

Deal Origination Executive Search For Sales Teams Corporate Development For Founders For Agencies For Investors Signal-Based Outbound Competitive Intelligence Funding Signals Competitor Monitoring

Explore

Companies Live Signals Markets Trends

Resources

Signal Checker Blog Integrations FAQ Contact Pricing
Login Start Free
Lonza logo — Making the Medicines of Tomorrow

Lonza

Making the Medicines of Tomorrow

Founded 1897 Switzerland Basel, Switzerland 19222 employees

General Information

Company Name Lonza
Founded Year 1897
Location Switzerland Basel, Switzerland +29
Employees 19222
Social

Get notified when Lonza moves

Funding, new markets, leadership changes, hiring surges — one e-mail, only when something happens.

Free · no account needed

AI Insight

Bounce Watch AI
2 months ago

Lonza is strategically advancing its leadership in the CDMO space, evidenced by a new licensing agreement for its ADC platform and the launch of an enhanced integrated DNA-to-IND offering designed to accelerate client therapies. This innovation and platform expansion are driving significant market penetration, with the company now partnering with 1,500 small biotech firms globally. Coupled with active hiring and a strong commitment to sustainable practices, Lonza is poised for continued growth and market influence.

Signal Types
Partnership Product Launch Traction Hiring Recognition Event Participation
Strategic Labels
Platform Expansion Service Innovation Market Penetration
Next Move: Expansion
·
Impact: 9/10
·
Ideal For: Life Sciences Institutional Investors

About Lonza

Lonza, with its slogan "Making the Medicines of Tomorrow," stands as a pioneer in the CDMO industry. Established in 1897 in Switzerland, it leverages over a century of expertise to transform breakthrough innovations into viable therapies. As the first and original CDMO, the company maintains a dynamic, agile, and forward-focused approach.

Currently, Lonza employs around 18,500 individuals globally, delivering comprehensive and integrated solutions that cater to complex customer needs. As one of the largest Western CDMOs, it emphasizes quality, safety, and reliability to swiftly and efficiently bring life-enhancing and life-saving treatments to market.

With no recent investment details disclosed, Lonza remains an attractive choice for investors looking for established entities with a significant industry footprint. The company's enduring legacy and commitment to fostering an inclusive environment ensure that it remains at the forefront of healthcare and pharmaceutical advancements.

Taxonomy: CDMO, Pharmaceutical Ingredients, Bioscience, Biopharmaceuticals, Custom Manufacturing, Life Science Ingredients, Cell Therapy, Gene Therapy, Capsules, Lean Manufacturing, Quality and Safety, Integrated Solutions, Therapies Development, Agile Manufacturing

Services & Products

Integrated Biologics
Advanced Synthesis
Specialized Modalities
Drug Development and Manufacturing
Regulatory Affairs CMC Services

Target Customers

Biopharmaceutical Companies Pharmaceutical Companies Biotech Startups Research Institutions Healthcare Industry

No funding data available for Lonza yet.

Get notified when Lonza raises funding

Latest News

View All
JPM25, Day 1: GSK's billion-dollar bet, Bayer's trial first, Lilly buys Scorpion, and more — Fiercebiotech.com
JPM25, Day 1: GSK's billion-dollar bet, Bayer's trial first, Lilly buys Scorpion, and more
Fiercebiotech.com Jan 13, 2025

Lonza Alternatives & Competitors

Lonza vs
Cognate BioServices
Cognate BioServices

Cognate BioServices is a contract development and manufacturing organization for cell and gene-media...

Lonza vs
RoslinCT
RoslinCT United Kingdom

Your Advanced Cell & Gene Therapy CDMO Partner

Private Equity
350 employees
Biotechnology, Manufacturing
Lonza vs
Celonic Group
Celonic Group Switzerland

Biologics Development and Manufacturing CDMO helping to bring life-saving and improving drugs effect...

320 employees
Biotechnology

FAQ About Lonza

Making the Medicines of Tomorrow
Lonza was founded in 1897.
Lonza is headquartered in Basel, Switzerland.
Lonza has approximately 19222 employees.
Lonza offers: Integrated Biologics, Advanced Synthesis, Specialized Modalities, Drug Development and Manufacturing, Regulatory Affairs CMC Services.
Top alternatives and competitors to Lonza include Cognate BioServices, RoslinCT, Celonic Group, Batavia Biosciences, ProBio. These companies operate in related industries and serve comparable markets. You can compare them side by side on Bounce Watch.
Lonza and Cognate BioServices are both companies in similar industries. Compare their funding, team size, growth signals, and market position on Bounce Watch to see which one fits your needs.

Don't just browse. Track.

Signal Tracker monitors Lonza and millions of companies for funding rounds, hiring surges, product changes, and 40+ signal types — so you never miss an opportunity.

Start Tracking — Free

One analytics cookie (Google Analytics). Cookie Policy